2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5938 Arlocabtagene autoleucel (arlo-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma: Analysis of on-target, off-tumor safety

Jesús G. Berdeja, MD, Omar Nadeem, MD2, Myo Htut, MD3, Larry D Anderson Jr, MD, PhD4, Mehmet Kocoglu, MD5, Tara Gregory, MD6, Adriana Rossi, MD7, Thomas Martin, MD8, Luciano J. Costa, MD, PhD9, Wei-Ming Kao, MD, PhD10, Noah Kaitz, PhD11, Ziyan Guo, PhD12, Safiyyah Ziyad, PhD13, Kristina Jordahl, PhD14, Sumeena Bhatia15, Susan Bal, MD16
1 Greco-Hainsworth Tennessee Oncology Centers for Research, Nashville, Tennessee, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 City of Hope Comprehensive Cancer Center, Duarte, California, United States
4 Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
5 University of Maryland, Baltimore, Maryland, United States
6 Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, Colorado, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 University of California, San Francisco, California, United States
9 University of Alabama at Birmingham, Birmingham, Alabama, United States
10 Bristol Myers Squibb, Princeton, New Jersey, United States
11 Bristol Myers Squibb, Princeton, New Jersey, United States
12 Bristol Myers Squibb, Princeton, New Jersey, United States
13 Bristol Myers Squibb, Princeton, New Jersey, United States
14 Bristol Myers Squibb, Princeton, New Jersey, United States
15 Bristol Myers Squibb, Princeton, New Jersey, United States
16 University of Alabama at Birmingham, Birmingham, Alabama, United States

Introduction: Arlo-cel is a potential first-in-class chimeric antigen receptor (CAR) T cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). A phase 1 study of arlo-cel (NCT04674813) demonstrated deep and durable responses with well-tolerated safety in both early- and late-line patients with relapsed/refractory multiple myeloma (RRMM). GPRC5D is highly expressed on myeloma cells and has limited expression in hard-keratinized tissues, leading to mechanism-based on-target/off-tumor (OTOT) toxicities commonly observed with GPRC5D-targeted therapies. Characterizing OTOT toxicities is key to defining the safety profile of GPRC5D-targeted therapies and improving long-term patient outcomes. Here we report a comprehensive characterization of OTOT toxicities from cohort A of the phase 1 study of arlo-cel in heavily pretreated patients with RRMM.

Methods: Patients with RRMM who received ≥3 prior lines of therapy (pLOT) including a proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy were enrolled. Following lymphodepletion, a single infusion of arlo-cel was administered at a dose of 25, 75, 150, 300, or 450 million (M) CAR T cells. The primary objective was safety; secondary objectives included clinical activity per IMWG Uniform Response Criteria and pharmacokinetics. Exploratory assessments were: i) OTOT profile including incidence, severity, time to onset, and time to resolution, specifically for skin, nail, and oral toxicities, and ii) correlative analysis of serum biomarkers and OTOT toxicities. Each contiguous OTOT toxicity (e.g., dysgeusia) was counted once per patient and graded at its maximum severity, with recurrences occurring >1 day after resolution counted as distinct events.  

Results: Of the 86 patients enrolled in cohort A, a total of 84 received arlo-cel across all doses combined; 41 (48.8%) patients experienced an OTOT toxicity and all events were grade ≤2. Baseline (BL) characteristics were generally similar between patients who had or did not have an OTOT toxicity, except a numerically higher proportion of patients without an OTOT toxicity had extramedullary plasmacytoma (16 [39.0%] and 22 [51.2%]) or high-risk cytogenetics (14 [34.1%] and 23 [53.5%], respectively); 73.2% and 79.1% patients were triple-class refractory. Of patients who experienced an OTOT toxicity, 16 (39%) experienced 1 OTOT event, 14 (34.1%) experienced 2 events, 4 (9.8%) experienced 3 events, and 7 (17.1%) experienced ≥4 OTOT toxicities. In patients who had ≥1 OTOT toxicity of any type, median time to first OTOT toxicity was 15 days (range, 1–121) and to subsequent toxicities from first event was 31 days (range, 12–253). Specifically, 26/41 (63.4%) patients reported skin, 19/41 (46.3%) nail, and 27/41 (65.9%) oral adverse events (AEs); 14/41 (34.1%) had both skin and nail AEs, 14/41 (34.1%) had skin and oral AEs, 12/41(29.3%) had nail and oral AEs, and 9/41 (22.0%) had all skin, nail, and oral AEs. Resolution of OTOT toxicities was observed in the majority of patients reporting skin (n=23/26, 88.5%), nail (n=14/19, 73.7%), and oral (n=20/27, 74.1%) AEs. The majority of events resolved without intervention, irrespective of whether patients experienced single or multiple events. Median time to resolution was 20 (range, 1.0–467.0) days for skin, 78.0 (29.0-131.0) days for nail, and 16.0 (7.0–77.0) days for oral AEs. In a correlative analysis of serum biomarkers, the levels of baseline (screening) for soluble BCMA, C-reactive protein (CRP), or ferritin did not significantly differ between patients with and without an OTOT toxicity. Additional data on the association of response with OTOT occurrence and other serum biomarkers will be presented.

Conclusions: OTOT toxicities represent a manageable safety profile for arlo-cel, characterized by a relatively low frequency of multiple events, high rates of resolution, and limited need for intervention with all low-grade events. No clear differences in baseline sBCMA, CRP, or ferritin levels were observed between patients with and without OTOT toxicity. Ongoing correlative analyses will further define associations between occurrence of OTOT toxicity, efficacy outcomes, and biomarker profiles. Together with previously reported data, these results support arlo-cel as a potential treatment option for patients with RRMM.

Jesús G. Berdeja, MD: Moderna - Honoraria; Takeda - Honoraria; Roche - Honoraria; BMS - Honoraria; Regeneron - Honoraria; Kyowa Kirin - Honoraria; Sanofi - Honoraria; GSK - Honoraria; Cartesian Therapeutics - Honoraria; CARsgen - Honoraria; 2 Seventy Bio - Honoraria; Janssen - Honoraria; Kite - Honoraria; Pfizer - Honoraria; Karyopharm Therapeutics - Honoraria; K36 Therapeutics - Honoraria; Genentech - Honoraria; C4 Therapeutics - Honoraria; Johnson & Johnson - Honoraria; Astra Zeneca - Honoraria; Gracell - Honoraria; Therapeutics - Honoraria; Celularity - Honoraria; Galapagos - Honoraria; Caribou Therapueutics - Honoraria; Therapeutics - Research Funding; Karyopharm Therapeutics - Research Funding; K36 Therapeutics - Research Funding; Galapagos - Research Funding; Astra Zeneca - Research Funding; Takeda - Research Funding; Genentech - Research Funding; Kelonia - Research Funding; Gracell - Research Funding; Moderna - Research Funding; Regeneron - Research Funding; Cartesian Therapeutics - Research Funding; Janssen - Research Funding; GSK - Research Funding; BMS - Research Funding; 2 Seventy Bio - Research Funding; Kite - Research Funding; Kyowa Kirin - Research Funding; Celularity - Research Funding; Ichnos Sciences - Research Funding; Johnson & Johnson - Research Funding; CARsgen - Research Funding; Sanofi - Research Funding; Caribou Therapueutics - Research Funding; Pfizer - Research Funding; Simcere Zaiming - Research Funding; Roche - Research Funding; Juno Therapeutics - Research Funding; C4 Therapeutics - Research Funding; C4 Therapeutics - Consultancy (Includes expert testimony); Therapeutics - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); K36 Therapeutics - Consultancy (Includes expert testimony); Kyowa Kirin - Consultancy (Includes expert testimony); Astra Zeneca - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Moderna - Consultancy (Includes expert testimony); 2 Seventy Bio - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Whitehawk Therapeutics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Gracell - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Cartesian Therapeutics - Consultancy (Includes expert testimony); Caribou Therapueutics - Consultancy (Includes expert testimony); CARsgen - Consultancy (Includes expert testimony); Galapagos - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Celularity - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)